key: cord-0900913-o2j6jrrd
authors: Mansi, Laura; Spehner, Laurie; Daguindau, Etienne; Bouiller, Kevin; Almotlak, Hamadi; Stein, Ulrich; Bouard, Adeline; Kim, Stefano; Klajer, Elodie; Jary, Marine; Meynard, Guillaume; Vienot, Angélique; Nardin, Charlée; Bazan, Fernando; Lepiller, Quentin; Westeel, Virginie; Adotévi, Olivier; Borg, Christophe; Kroemer, Marie
title: Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients
date: 2021-03-26
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.03.033
sha: 26c4027c042f02a126b8d6873b23453348037af8
doc_id: 900913
cord_uid: o2j6jrrd

BACKGROUND: Cancer patients are considered as highly vulnerable to COVID-19 pandemic. However, delaying cancer specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients’ immune system responds to SARS-CoV-2 virus. METHODS: We have started a prospective monocentric trial entitled COV-CREM (NCT04365322) on April 2020. The primary trial objective was to assess specific immune response’s intensity and diversity to SARS-CoV-2 for infected patients. RESULTS: In this study, we showed that cancer patients (28 solid tumors, 11 hematological malignancies) exposed to SARS-CoV-2 produced high rate of specific antibodies, as observed in patients without cancer history (n=29). However, our results highlight a lack in the generation of T-cell responses against CoV-N, M and S proteins from SARS-CoV-2 virus, suggesting that cancer patients failed to mount a protective T-cell immunity. Nevertheless, SARS-CoV-2 infection did not impair established immune memory since specific responses against common viruses was not hampered in cancer patients. CONCLUSION: Given the severity and the unknown evolution of the ongoing COVID-19 pandemic, it is of fundamental importance to integrate cancer patients in vaccination programs.

Today's fight against the SARS-CoV-2 virus generates a scientific emulation that brings together researchers 53 from all horizons. Older age and medical comorbidities are the main risk factors for severe outcomes and higher 54 mortality from COVID-19 infection [1] . This is why cancer patients are considered as highly vulnerable [2, 3] . (Fig. 1A) . In line with a potential cross reactivity with previous 105 coronavirus exposition, recognition of CoV-S, M and N proteins by T-cells was observed in respectively 33.3%, 106 33.3% and 14.3% of the healthy donors tested (Fig. 1B) . Furthermore, SARS-CoV-2 elicited specific immune 107 responses against CoV-M and CoV-N in 58.6 and 65.5% of the patients without a cancer history (p≤0.05 and 108 p≤0.01 respectively) (Fig. 1B, middle and right panel) . solid tumors compared to patients without a cancer history (35.7% vs 58.6%, p=0.0348). The one against CoV-119 M tends to be lower (39.3% vs 58.6%, p=0.12) (Fig. 1B) . Interestingly, two cancer patients without peripheral 120 SARS-CoV-2 specific T-cells had prolonged virus RNA detection after symptoms resolution, while no 121 prolonged RNA production was reported in patients with specific adaptive immunity. The SARS-CoV-2 specific 122 T-cells absence was not correlated to clinical determinants. Similarly, lymphopenia and lymphocyte subset 123 distribution did not account for the lack of SARS-CoV-2 specific immunity ( Table 1) .

The other immunological issue for cancer patients is the potential risk that SARS-CoV-2 virus-mediated 125 infection dampens pre-existing memory T-cell repertoire. To investigate this issue, we concomitantly measured 126 the reactivity against common viruses using IFNγ ELISpot assay. Median intensities and frequencies were 127 similar across all patients' groups. (Fig. 1C) . This demonstrated that recent history of COVID-19 did not hamper 128 viral memory T-cell pool in patients with or without cancers. It suggests that the lack of SARS-CoV-2 specific 129 T-cells is related to a weak immune adaptive response initiation rather than a global T-cell dysfunction.

We then analyzed the SARS-CoV-2 humoral responses. We compared the serology index between our 131 patients' cohorts ( Fig. 1D) . The median serology index in patients without cancer history was (5.6 S/CO [IQR: 132 2.9-6.6] and statistically lower when compared to patients with solid tumors 6.9 S/CO [IQR: 5.0-8.3] (p=0.016).

In contrast patients with hematological malignancies had a median serology index equal to 3.25 S/CO [IQR 0.1-134 6.3] that was statistically lower when compared to both patients with solid tumors and without cancer history 135 (p=0.0017 and p=0.052). A heatmap was generated, using the online Morpheus software 136 (https://software.broadinstitute.org/morpheus/), to correlate all immunological parameters investigated (Fig. 1E) .

These results unravel that SARS-CoV-2 infection is associated with a lack of adaptive T-cell immunity in cancer 138 patients. In addition, a discrepancy was unraveled, in the context of cancer history, between SARS-CoV-2 139 seroconversion and the presence of memory T-cells. 

Clinical course and risk factors for mortality of adult inpatients 206 with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of COVID-19-infected cancer 209 patients: a retrospective case study in three hospitals within Wuhan

Cancer patients in SARS-CoV-2 infection: a nationwide 212 analysis in China

Patients with cancer appear more vulnerable to SARS-COV-2: a 214 multi-center study during the COVID-19 outbreak

COVID-19 mortality in patients with cancer 217 on chemotherapy or other anticancer treatments: a prospective cohort study

Clinical impact of COVID-19 on 220 patients with cancer (CCC19): a cohort study

Immunology of COVID-19: Current State of the 222

The many faces of the anti-COVID immune response

SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Preliminary Identification of Potential Vaccine Targets for the COVID-19